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Background: Triple negative breast cancer (TNBC) is characterized by lack of expression of both estrogen and
progesterone receptor as well as lack of overexpression or amplification of HER2. Despite an increased probability
of response to chemotherapy, many patients resistant to current chemotherapy regimens suffer from a worse
prognosis compared to other breast cancer subtypes. However, molecular determinants of response to
chemotherapy specific to TNBC remain largely unknown. Thus, there is a high demand for biomarkers potentially
stratifying triple negative breast cancer patients for neoadjuvant chemotherapies or alternative therapies.
Methods: In order to identify genes correlating with both the triple negative breast cancer subtype as well as
response to neoadjuvant chemotherapy we employed publicly available gene expression profiles of patients, which
had received neoadjuvant chemotherapy. Analysis of tissue microarrays as well as breast cancer cell lines revealed
correlation to the triple negative breast cancer subtype. Subsequently, effects of siRNA-mediated knockdown on
response to standard chemotherapeutic agents as well as radiation therapy were analyzed. Additionally, we
evaluated the molecular mechanisms by which SFRP1 alters the carcinogenic properties of breast cancer cells.
Results: SFRP1 was identified as being significantly overexpressed in TNBC compared to other breast cancer
subtypes. Additionally, SFRP1 expression is significantly correlated with an increased probability of positive response
to neoadjuvant chemotherapy. Knockdown of SFRP1 in triple negative breast cancer cells renders the cells more
resistant to standard chemotherapy. Moreover, tumorigenic properties of the cells are modified by knockdown, as
shown by both migration or invasion capacity as well reduced apoptotic events. Surprisingly, we found that these
effects do not rely on Wnt signaling. Furthermore, we show that pro-apoptotic as well as migratory pathways are
differentially regulated after SFRP1 knockdown.
Conclusion: We could firstly show that SFRP1 strongly correlates with the triple negative breast cancer subtype
and secondly, that SFRP1 might be used as a marker stratifying patients to positively respond to neoadjuvant
chemotherapy. The mechanisms by which tumor suppressor SFRP1 influences carcinogenic properties of cancer
cells do not rely on Wnt signaling, thereby demonstrating the complexity of tumor associated signaling pathways.
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Triple negative breast cancer (TNBC) is defined by the
lack of both estrogen receptor (ER) and progesterone re-
ceptor (PR) expression as well as overexpression or am-
plification of the human epidermal growth factor receptor
HER2 [1-3]. Patients suffering from TNBC are not eligible
for endocrine or HER2 targeted therapies, thus rendering
chemotherapy the only therapeutic option, which may be
accompanied by antiangiogenic approaches such as bevaci-
zumab in the palliative setting [2,4,5]. Up to 15% of all
breast cancer patients are diagnosed with TNBC [3]. Due
to high recurrence rates and an increased risk of visceral
and cerebral metastases these patients have a poorer prog-
nosis in comparison to other breast cancer subtypes [6-8].
However, patients suffering from TNBC do have an in-
creased probability of positive response to anthracycline/
taxane- containing neoadjuvant chemotherapy. Thus, by
achieving a pathologic complete response after neodaju-
vant chemotherapy the prognosis is as good as in other
breast cancer subtypes [9]. Consequently, as chemotherapy
sensitivity is one of the most important prognostic factors,
it is inevitable to identify biomarkers and potential media-
tors of chemotherapy sensitivity in patients with TNBC.
The scientific goal of this study was to identify bio-
markers, which may serve as mediators of chemotherapy
sensitivity in TNBC. By using global gene expression pro-
files of patients receiving neoadjuvant chemotherapy we
could identify secreted frizzled receptor protein 1 (SFRP1) as
being correlated with the triple negative breast cancer sub-
type. Furthermore, we found a positive correlation of SFRP1
expression and response to neoadjuvant chemotherapy.
SFRP1 has been described to antagonize canonical Wnt
signaling by binding to Wnt proteins or Wnt receptors,
thereby inhibiting their downstream signaling activity [10].
In a plethora of solid tumors, including colorectal cancer,
ovarian cancer, prostate cancer and lung cancer, it has been
shown that SFRP1 is inactivated by promoter hypermethy-
lation [11-15]. In breast cancer, hypermethylation of the
SFRP1 promoter has been correlated to poor prognosis,
presumably due to elevated levels of Wnt signaling [16,17].
By analyzing the molecular role of SFRP1 in triple
negative breast cancer cells via siRNA mediated knock-
down we found changes in carcinogenic properties of
breast cancer cells, e.g. increased migration and invasion
potential as well as reduced apoptotic events. Further-
more, we observed an increased resistance to standard
cytostatic agents. Surprisingly, although SFRP1 is known
to act via canonical Wnt signaling, our data suggests
that its influence on triple negative breast cancer cells is
apparently not mediated via this pathway.
In summary, we could show that tumor suppressor
and Wnt signaling antagonist SFRP1 is correlated with
the most aggressive subtype of breast cancer, i.e. triple
negative breast cancer; but also with positive response toneoadjuvant chemotherapy. This makes SFRP1 a potential
biomarker for future stratification of triple negative breast
cancer patients. Additionally, SFRP1 seems to be involved
in regulatory processes necessary for tumorigenic cancer
cells, e.g. regulation of apoptosis as well as migration and
adhesion processes. Surprisingly, however, these mecha-
nisms are not mediated by canonical Wnt signaling.
Results
SFRP1 expression correlates with the TNBC subtype and
response to neoadjuvant chemotherapy
In order to identify genes involved in chemotherapy re-
sponse in patients suffering from TNBC we made use of a
published dataset analyzing global gene expression profiles
of breast cancer patients receiving neoadjuvant chemother-
apy [18]. This dataset combines pretreatment gene expres-
sion profiles with response to neoadjuvant chemotherapy,
e.g. showing either residual disease (n = 99) or pathologic
complete response (n = 34). By analyzing both gene ex-
pression profiles as well as response to neoadjuvant che-
motherapy we could firstly, show that SFRP1 expression
correlates with the triple negative breast cancer subtype
and secondly, demonstrate association between expression
of SFRP1 and positive response to neoadjuvant chemother-
apy, i.e. achievement of a pathologic complete response
(Figure 1A, Tables 1, 2).
We next sought to analyze the expression of SFRP1 in
breast cancer tissue specimen. Therefore, we performed
immunohistochemical analyses of tissue microarrays of
breast cancer patients previously categorized as being ei-
ther TNBC or non-TNBC. We detected different levels
of SFRP1 expression mostly located in the tumor tissue
(Figure 1B). When analyzing the distinct scores of ex-
pression of SFRP1 we found strong correlation of SFRP1
expression and the triple negative breast cancer subtype
(Figure 1C).
In addition, by using quantitative real time PCR and
western blot analyses we found expression of SFRP1 in 5
out of 6 triple negative breast cancer cell lines (HCC-1937,
MDA-MB-468, BT-20, MDA-MB-453 and HCC-1806),
whereas no expression was detected in the TNBC cell line
MDA-MB-231 as well as the non-TNBC cell lines SKBR-3
or MCF-7 (Figure 1D). These results clearly demonstrate a
correlation of expression of SFRP1 and the triple negative
breast cancer subtype. Additionally, there seems to be a
link between the response to neoadjuvant chemotherapy
and expression of SFRP1.
Knockdown of SFRP1 increases resistance against both
chemotherapeutic agents as well as radiotherapy in triple
negative breast cancer cells
In order to analyze the role of SFRP1 in triple negative
breast cancer cells, we performed siRNA-mediated knock-
down of SFRP1 in the triple negative breast cancer cell
Figure 1 Expression of SFRP1 correlates with the triple negative breast cancer subtype. A) SFRP1 was found to be upregulated in TNBC
compared to non-TNBC; shown here are all three probesets 202035_s_at, 202036_s_at and 202037_s_at (TN = triple negative). B) Expression of
SFRP1 in breast cancer tissue specimens of 362 patients (TNBC = 37patients); scores 0 (negative), 1 (weak positive), 2 (positive), 3 (strong positive).
C) Boxplot analysis of immunohistochemical staining. D) Protein and mRNA levels of SFRP1 in different breast (cancer) cell lines (non-tumorigenic
epithelial cell line: MCF-10A, TNBC cell lines: HCC1937, MDA-MB-468, BT-20, MDA-MB-453, HCC 1806 and MDA-MB-231; non-TNBC cell lines SKBR-3
and MCF-7) (n.d. = not detected).
Table 1 Expression of SFRP1 correlates with the triple negative breast cancer subtype
Probeset Gene ID Adjusted p-value Upregulated Mean non-TN Mean TN
202035_s_at SFRP1 1.4 10E − 5 TNBC 3.844 5.879
202036_s_at SFRP1 5.5 10E − 6 TNBC 5.734 7.966
202037_s_at SFRP1 3.0 10E − 6 TNBC 6.187 8.424
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Table 2 Expression of SFRP1 correlates with positive response to neoadjuvant chemotherapy
Probeset Gene ID Adjusted p-value Upregulated Mean RD Mean pCR
202035_s_at SFRP1 0.017 pCR 4.993 6.833
202036_s_at SFRP1 0.035 pCR 7.116 8.881
202037_s_at SFRP1 0.021 pCR 7.553 9.364
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down was proven via quantitative real-time PCR and
Western Blot analysis (Figure 2A).
We next sought to evaluate the influence of SFRP1
knockdown to standard triple negative breast cancerFigure 2 Downregulation of SFRP1 renders triple negative breast can
and protein (right) levels of SFRP1 after siRNA mediated knockdown, as de
sensitivity of MDA-MB-468 and HCC-1806 after SFRP1 knockdown was dete
cells after treatment with cytotoxic agents (significance in MDA-MB-468 for
for 500 pM-50 nM and for cisplatin *p < 0.05 for 50 nM-50 μM; no significachemotherapy. Therefore, we analyzed the response to
chemotherapeutic agents after SFRP1 knockdown by cell
viability assay. Interestingly, downregulation of SFRP1 ex-
pression rendered triple negative breast cancer cell line
MDA-MB-468 more resistant to the chemotherapeuticcer cells more resistant to standard chemotherapy. A) mRNA (left)
termined by qPCR and Western-Blotting, respectively. B) Chemotherapy
rmined using MTT cell viability assay of control vs. SFRP1 knockdown
paclitaxel ***p < 0.001 for 10 pM-1 nM, for doxorubicin ***p < 0.001
nt changes were found in HCC-1806), error bars = SD, n = 3.
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left column). Another triple negative breast cancer cell
line, HCC-1806, showed only increased resistance to pacli-
taxel (Figure 2B, right column). Thus, the knockdown of
SFRP1 renders cancer cells more resistant to standard
chemotherapeutic treatment.
Knockdown of SFRP1 enhances the carcinogenic
properties of triple negative breast cancer cells
Next, we sought to explore the impact of SFRP1 on tumori-
genic properties of breast cancer cells. Hence, we analyzed
both migration as well as invasion potential of breast can-
cer cell line MDA-MB-468 after SFRP1 knockdown. The
migratory potential was not significantly increased after
knockdown. However, invasion through matrigel-coated
membranes was significantly increased by about 30% after
SFRP1 knockdown (Figure 3A, B (left, center)). Addition-
ally, we thought whether the rate of apoptosis is influences
upon SFRP1 knockdown. Therefore, we analyzed the
amount of apoptotic and necrotic cells via flow cytometry.
We found a slight decrease of apoptotic as well as necrotic
cells after SFRP1 knockdown (Figure 3C, D). These results
demonstrate a link between expression of SFRP1 and car-
cinogenic properties of breast cancer cells.
The changes of tumorigenic potential of cells after SFRP1
knockdown do not rely on Wnt signaling
SFRP1 is known to antagonize Wnt signaling activity
via binding to either Wnt proteins or frizzled receptors,
thereby blocking the intracellular signaling cascade [17].
Thus, we hypothesized that loss of SFRP1 might activate
canonical Wnt signaling activity. Therefore, we performed
a TOP-Flash/FOP-Flash luciferase assay in order to analyze
the effects of SFRP1 knockdown on the triple negative
breast cancer cell line MDA-MB-468. Surprisingly, we
were not able to detect any changes in Wnt signaling activ-
ity of breast cancer cells after SFRP1 knockdown (Figure 4A
(left)). As Wnt signaling activity is known to be very low in
breast cancer cells, we made use of a known Wnt activator,
LiCl, in order to stimulate Wnt signaling activity [19-21].
Treatment of cells with LiCl leads to a significant increase
of Wnt signaling activity of about 30-fold. However, no
significant changes were found in SFRP1 knockdown cells
compared to control cells (Figure 4A (right)). Additionally,
when analyzing the cellular localization of β-Catenin by
immunofluorescence staining we were not able to detect
any enhanced nuclear localization of β-Catenin after
SFRP1 knockdown, typically a hallmark of activated Wnt
signaling (Figure 4B).
We also performed global gene expression profile ana-
lysis via microarray analysis after SFRP1 knockdown in
MDA-MB-468 cells. When analyzing effects on known
canonical Wnt target genes, we were not able to detect
any significant changes in gene expression (Table 3). Inorder to validate the microarray gene expression analysis
data, we also performed quantitative real time PCR ana-
lysis. Although we found a decrease of approximately 60%
in SFRP1 expression upon siRNA mediated knockdown,
no significant changes of known Wnt target genes were
observed (Figure 4C). Furthermore, we analyzed the ex-
pression levels of known members of the non-canonical
Wnt signaling pathway [22-24]. However, we could not
detect any significant changes in expression levels of these
genes (Figure 4D). Since the Wnt signaling pathway is also
correlated with the phenomenon of epithelial to mesen-
chymal transition, a process in which epithelial cells gain
characteristics of mesenchymal cells, e.g. increased migra-
tory or invasive potential, we also analyzed the expression
levels of a plethora of known EMT related genes [25]. Al-
though we found an increase in known EMT related genes
N-Cadherin (CDH2) as well as TWIST, the majority of
EMT genes remained unaffected after SFRP1 knockdown
(Figure 4E). Thus, the effects of SFRP1 knockdown on car-
cinogenic properties on triple negative breast cancer cells
do not appear to be mediated by elevated levels of canon-
ical nor non-canonical Wnt signalling.
SFRP1 influences effects of cell adhesion and apoptosis
To gain insights into the mechanism underlying effects of
SFRP1 knockdown on carcinogenic properties of triple
negative breast cancer cells, we performed global gene ex-
pression profiling after SFRP1 knockdown followed by
gene ontology analysis. When analyzing the list of genes
showing upregulation of more than 30% after knockdown
by using DAVID gene ontology database (http://david.
abcc.ncifcrf.gov, [26]) we found several genes involved
in cell adhesion, cell motion as well as signaling activity
(Table 4). On the other hand, when analyzing genes
showing downregulation of more than 25% after SFRP1
knockdown, we primarily found genes involved in posi-
tive regulation of apoptosis (Table 5), which is consistent
with our observed decrease in apoptotic events in these
cells (Figure 3C, D). Thus, SFRP1 knockdown positively
regulates mechanisms of cell adhesion as well as the sur-
vival of cells presumably by inhibiting signals usually asso-
ciated with apoptosis.
Discussion
Triple negative breast cancer is the most aggressive breast
cancer subtype associated with poor prognosis as well as
high recurrence rates. Since patients suffering from TNBC
do have an unfavorable prognosis mostly due to limited
therapeutic options, this cancer subtype has gained much
attention regarding the development of novel targeted
therapies. However, a high number of TNBC patients do
positively respond to neoadjuvant chemotherapy. As a re-
sult, achieving a pathologic complete response (pCR) is
correlated with good prognosis similar to other breast
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responding to neoadjuvant chemotherapy would greatly
improve the therapeutic options for TNBC. Other TNBC
patients, however, would need to be treated differently,
e.g. by anti-angiogenic treatment.
By using a published dataset analyzing differential gene
expression profiles as well as response to neoadjuvantFigure 3 Downregulation of SFRP1 changes carcinogenic properties o
migration and invasion filters after SFRP1 knockdown in MDA-MB-468 cells
knockdown revealed increase in migration of about 15% and increase in in
C/D) Flow cytometry analysis using Annexin V staining showed a slight de
or necrotic events (C: Q1 and Q2).chemotherapeutic treatment of breast cancer patients we
could show a correlation of SFRP1 expression and the
triple negative breast cancer subtype.
We could demonstrate that breast cancer cell lines
showing increased SFRP1 expression are associated with
the triple negative phenotype, similar to published re-
sults showing higher expression in basal like cancer cellf triple negative breast cancer cells. A) Representative pictures of
. B) Quantitative analysis of migration and invasion assays after SFRP1
vasion potential of about 30% ((*p < 0.05), error bars = SD, n = 3)
crease of cells undergoing apoptotic (C: Q4) as well as late apoptotic
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mainly found increased expression of SFRP1 in triple
negative breast cancer cell lines, which molecularly belong
to basal A subtype described by Neve et al. (HCC1937,
MDA-MB-468 and BT20) [27]. Cell lines of basal A sub-
type display more epithelial characteristics, whereas basal
B cell lines are shown to be more invasive presumably due
to spindle-like morphology displaying mesenchymal as
well as stem/progenitor-like characteristics.
Furthermore, the basal A subtype has been correlated
with increased response to neoadjuvant chemotherapy
when compared to the basal B subtype [28,29]. In line withFigure 4 Influence of SFRP1 on carcinogenic properties does not rely
changes in Wnt signaling activity upon SFRP1 knockdown in breast cancer
cells grown in starvation medium followed by Wnt stimulation using LiCl t
changes in cellular localization of β-Catenin after SFRP1 knockdown. C/D) m
members of the non-canonical Wnt signaling pathway (D) revealed no sig
related genes after SFRP1 knockdown. F) Model of action of SFRP1 in breathese observations we could show that expression of
SFRP1 is also correlated with the achievement of a patho-
logic complete response after neoadjuvant chemotherapy.
Thus, SFRP1 might become a useful biomarker to stratify
triple negative breast cancer patients, which might benefit
from neoadjuvant treatment. However, for clinical appli-
cations using SFRP1 expression as a prognostic biomarker,
a proper platform is needed e.g. immunohistochemistry
(IHC) or fluorescent in situ hybridization (FISH) followed
by conversion into dichotomous status [30].
SFRP1 belongs to the family of 5 secreted frizzled re-
ceptor proteins, which show homology to the frizzledon canonical Wnt signaling. A) Luciferase assays showed neither
cells grown in standard medium (left 3 rows), nor in breast cancer
reatment (right 3 rows). B) Immunofluorescence analysis showed no
RNA levels of known canonical Wnt target genes (C) as well as
nificant changes upon SFRP1 knockdown. E) mRNA levels of EMT
st cancer.
Table 5 Gene ontology analysis of genes showing
downregulation of < 75% after SFRP1 knockdown in
MDA-MB-468 cells
Term Count p-Value
Negative regulation of cell proliferation 19 1.60E-05
Positive regulation of apoptosis 20 5.00E-05
Positive regulation of programmed cell death 20 5.50E-05
Positive regulation of cell death 20 5.90E-05
Regulation of cellular localization 14 1.50E-04
Regulation of apoptosis 28 1.60E-04
Regulation of programmed cell death 28 1.90E-04
Induction of apoptosis by intracellular signals 7 2.00E-04
Regulation of cell death 28 2.00E-04



























Only 2 of several known Wnt target genes show increased expression after
SFRP1 knockdown (List of genes available from: The Wnt
homepage; www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes).
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has been described to antagonize canonical Wnt signal-
ing by binding to either Wnt ligand proteins or frizzled
receptors, thereby inhibiting the downstream signaling
cascade [17]. SFRP1 has been linked to a number ofTable 4 Gene ontology analysis of genes showing
upregulation of > 130% after SFRP1 knockdown in
MDA-MB-468 cells
Term Count p-Value
Intracellular signaling cascade 68 7.40E-04
Positive regulation of transferase activity 20 1.20E-03
Cell motion 31 2.20E-03
Regulation of transferase activity 26 2.20E-03
Biological adhesion 41 2.80E-03
Cell adhesion 41 2.90E-03
Positive regulation of kinase activity 18 4.40E-03
Monosaccharide transport 6 4.70E-03
Regulation of kinase activity 24 5.40E-03
Cell migration 20 5.60E-03solid tumors, e.g. colon cancer, ovarian cancer, prostate
cancer or breast cancer [11-17]. It has been shown that
the SFRP1 promoter is hypermethylated in these entities,
thereby inactivating SFRP1 expression and its protein
translation.
When analyzing the influence of loss of SFRP1 in triple
negative breast cancer cells we found an increase of
tumor-associated characteristics, e.g. increase in migration
and invasion capacity, reduced apoptotic events as well as
resistance to cytotoxic chemotherapy. Increased Wnt sig-
naling is known to regulate tumor progression mecha-
nisms as well as resistance to chemotherapy or radiation
[32-34]. Thus, we initially hypothesized that knockdown
of SFRP1 might result in increased Wnt signaling activity,
thereby promoting tumor-associated properties of cells.
This would be in line with previously published data
showing reduced xenograft growth after SFRP1 overex-
pression in breast cancer cells presumably due to blockade
of canonical Wnt signaling activity [35].
Surprisingly, however, we were neither able to detect
Wnt activation by TOPFlash luciferase assays, changes
in cellular localization of β-Catenin, nor detect any sig-
nificant upregulation of known Wnt target genes. There-
fore, we propose a different mechanism at which SFRP1
influences tumorigenic properties like invasion potential
or resistance to chemotherapeutic agents. However, a
Wnt dependent effect may also occur in triple negative
cancers as in vivo Wnt signals may be supplied from the
tumor stroma. Thus, Wnt dependent effects may also be
contributing to the in vivo responsiveness of triple nega-
tive breast cancer patients to chemotherapy.
In addition to its known role in Wnt signaling, recent
reports also demonstrate novel roles for SFRP1 signaling.
One report showed binding of SFRP1 to thrombospondin-
1, thereby inhibiting cancer cell adhesion and migration.
This binding was conducted via the netrin related motif of
SFRP1 [36]. These data are in accordance with our obser-
vation of increased invasiveness of SFRP1-depleted cells.
Another study demonstrated an increased sensitivity of
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TGF-β pathway is involved in epithelial to mesenchymal
transition (EMT) as well as cellular migration in later stage
mammary tumors, despite its known function as a tumor
suppressor in early stage malignancies [38-40]. However,
as expression of a majority of known EMT related genes
are not substantially altered upon SFRP1 knockdown
(Figure 4E), EMT may be of minor relevance in our ex-
perimental system. Recently, another study demonstrated
a link between reduction of SFRP1 and reduction of apop-
tosis in vitro [41]. By using global gene expression profiles
after SFRP1 knockdown, gene ontology analyses revealed
upregulation of genes involved in migration processes,
whereas genes involved in the positive regulation of apop-
tosis were downregulated (Tables 4, 5). Thus, chemother-
apy might be reinforced by inhibition of apoptosis after
SFRP1 knockdown. This view is supported by our obser-
vation of a slight decrease of apoptotic events upon SFRP1
depletion (Figure 3C, D). Apparently, pathways different
from Wnt signaling presumably regulate processes that
lead to increase of tumorigenic properties of cancer cells.Conclusions
Our study sheds light on the complex regulatory net-
work of mammary tumorigenesis and tumor progres-
sion, proposing a model in which SFRP1 regulates either
invasive processes via canonical Wnt signaling but also
via different pathways, e.g. TGF-β signaling as well as
apoptotic processes via so far unknown mechanisms
(Figure 4F).
Furthermore, we conclude that SFRP1 might be clin-
ically used to stratify patients, which suffer from triple
negative breast cancer for responding to neoadjuvant
chemotherapy. As the reduction of SFRP1 is in line with
increased aggressiveness of cancer cells, its overexpression
might be an approach to explore novel therapeutic projec-
tions [35]. Thus, an increased level of SFRP1 might
sensitize triple negative breast cancer patients towards
chemotherapy, thereby improving prognosis of this ag-
gressive breast cancer subtype. Nevertheless, future ana-
lyses have to be undertaken to explore the role of SFRP1
in regulating mammary tumor progression, particularly
progression of triple negative breast cancer.Methods
Cell culture, chemicals
The human mammary epithelial cell line MCF10a and the
cancerous cell lines HCC 1937, MDA-MB 468, BT-20,
MDA-MB 453, HCC 1806, MDA-MB 231, SKBR-3 and
MCF-7 were supplied from ATCC and cultured under rec-
ommended conditions. Medium, trypsin-EDTA, PBS, fetal
calf serum and horse serum were received from PAA
Laboratories.In order to chemically stimulate Wnt signaling, cells
were starved in medium without serum for 24 h followed
by incubation with 10 mM LiCl (SIGMA Aldrich), which
inhibits GSK3β, thereby activating Wnt signaling [19,21].
Microarray gene expression analyses
A published microarray dataset was used for differential
gene expression analysis [18]. For gene expression analysis
in patients, triple negative breast cancer was defined using
clinical measurements for ER, PR and HER2 as described
previously and compared to the remaining cases merged as
non-TNBC. Response to neoadjuvant chemotherapy was
defined as absence of invasive breast cancer cells at the time
of definitive surgery [42] and dichotomized as either pCR
(n = 34) or residual invasive disease (RD; n = 99). Among
cases with TNBC, 13 cases had pCR and 14 cases had RD.
Gene expression data was processed and normalized using
the robust multiarray average normalization algorithm as
implemented in R-package affy version 1.32.0 [43].
Differential gene expression between patient subgroups
was assessed using Welch's t statistic. The resulting p
values were adjusted for control of the false discovery rate
(FDR) according to Benjamini and Hochberg's method
[44]. Analyses were performed in R using the Bioconduc-
tor multitest package version 2.10.0 [45].
For microarray experiments after SFRP1 knockdown in
MDA-MB-468 cells, mRNA was converted into cDNA by
using Superscript Double-Stranded cDNA Synthesis Kit
(Invitrogen) according to manufactures protocol. Fluores-
cence labeling was performed using NimbleGen One-
Color DNA Labeling Kit followed by hybridization onto
arrays (NimbleGen human gene expression 12 × 135k ar-
rays) according to protocol. By using DEVA software raw
data was extracted. Further normalization was performed
using GeneSpring Software. Normalized values were
imported into gene ontology database DAVID (http://da-
vid.abcc.ncifcrf.gov; [26].
For expression analysis Wnt target genes were identi-
fied using the Wnt Homepage (http://www.stanford.edu/
group/nusselab/cgi-bin/wnt/target_genes).
Western Blot analysis
Cells were incubated with RIPA buffer (10 mM NaF,
1 mM Na3VO4, 10 mM β-Glycerophosphate, 7.6 mM Tris
pH 7.4, 52 mM NaCl, 0.4% Triton X-100, 0.8 mM EDTA,
proteinase inhibitor (SIGMA Aldrich). Protein quantifica-
tion was performed via BCA assay (Pierce) according to
the manufacturer’s protocol. SDS page electrophoresis and
blotting were performed using standard protocols. Detec-
tion was performed using SFRP1 antibody (SIGMA Al-
drich, SAB2900383) and β-Actin antibody (BioLegend,
clone # 2 F1-1) and SuperSignal West Pico Chemilumines-
cent Substrate (Pierce). Bands were visualized with AGFA
developer and fixer (AGFA).
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RNA isolation was performed using NucleoSpin RNA Kits
(Macherey-Nagel) with on-column DNase digestion. Re-
verse transcription for real-time quantitative polymerase
chain reaction (RT-qPCR) was performed using MMLV re-
verse transcriptase (USB (Affymetrix)) and Oligo-dT15
priming at 42°C for 1 hour and at 60°C for 10 minutes. A
cDNA equivalent of 50 ng total RNA was used as template
in a total reaction volume of 20 μl with Power SYBR Green
PCR mix (Invitrogen) on an Step One Plus cycler (ABI).
Primers were added at 0.375 μM each. Calculations were
based on the ΔΔCt method using two housekeeping genes
for normalization. Real time primer sequences can be
found in supplemental Table 1 (Additional file 1: Table S1).siRNA mediated mRNA knockdown
siRNA mediated knockdown assays were implemented
using SFRP1 siRNA (part no 4392422) and negative con-
trol siRNA (part no 4390844) (Applied Biosystems) in
combination with DharmaFECT (ThermoScientific) trans-
fection reagent according to the manufacturer’s protocol.
Efficacy of knockdown was analyzed by qPCR and West-
ern blotting 48 h – 72 h after transfection.Cell migration / invasion assay
For migration assays, cell culture inserts equipped with
8 μm membranes were used (Falcon). For invasion assays,
BioCoat Matrigel invasion chambers (BD Biosciences) were
used according to the manufacturer’s protocols. Briefly,
24 – 48 h after transfection, 2 – 5 ×104 cells were
seeded into cell culture inserts in medium without
serum. The lower chamber was filled with medium con-
taining serum as chemoattractant. 48 – 96 h after seed-
ing cells, which passed the membranes, were fixed and
stained using Diff-Quik staining set according to manu-
facturer’s protocol (Medion Diagnostics). Stained filters
were mounted on microscope slides with VitroClud
(Langenbrinck). Quantitative analysis was done by cell
counting using Image J software.Luciferase assay
Luciferase assays were performed using TOPFlash or FOP-
Flash plasmids (addgene plasmid numbers 1256 and
12457, respectively) along with renilla normalization con-
struct (pRL-TK, Promega) using Lipofectamine 2000 (Invi-
trogen). Luciferase constructs were transfected 48 h after
siRNA transfection. Starvation medium as well as normal
medium was changed the next day. After additional 24 h,
cells were harvested and processed according to the Dual-
Glo Luciferase protocol (Promega). Relative Luciferase ac-
tivity was normalized to the activity of the FOPFlash
mutant vector control.Immunohistochemistry/Immunocytochemistry
The study was approved by the local ethical review commit-
tee (Research ethics committee of the Medical Association
Westfalen-Lippe and Westphalian Wilhelms University;
ethical vote: 2013-156-f-S). We used tissue microarrays of
362 patients. Of these, 37 were diagnosed as being TNBC
by missing expression of ER, PR and HER2. Immunohisto-
chemistry of formalin-fixed, paraffin-embedded tissue mi-
croarrays was performed using primary antibody (SFRP1,
Epitomics, clone# EPR7003) and biotinylated second-
ary antibodies (DAKO). Detection was performed using
Chromogen Red (DAKO) and H&E (Merck). Slides
were embedded with Scientific Cytoseal (Thermo Scien-
tific Fisher).
For immunocytochemistry, cells were fixed with phos-
phate buffered formalin. Cells were blocked with 10% Aur-
ion (DAKO) in PBS for 1 h. Cells were washed and
incubated with primary antibody (β-Catenin, Cell Signaling,
# 9587) diluted with Dako REALTM Antibody Diluent
(overnight at 4°C). Fluorescent visualization was carried out
using suitable Alexa Fluor-conjugated secondary antibody
(1:600) together with 4′,6-diamidino-2-phenylindole (1:400)
in in Dako REALTM Antibody Diluent) for 1 h at RT.
Chemotherapy sensitivity assay
For analysis of chemotherapy sensitivity, cells were incu-
bated with cytotoxic agents using decreasing concentra-
tions: paclitaxel (10 pM - 1 μM), doxorubicin hydrochloride
(500 pM - 50 μM), cis-diamineplatinum II dichloride
(50 nM - 5 mM). After 96 hours, cell viability was deter-
mined via MTT (Thiazolyl Blue Tetrazolium Bromide) (all
substances were received from SIGMA Aldrich) according
to the manufacturer’s protocol. Measurements were per-
formed at least in triplicates. Significance was calculated
via one-side Welch’s t-test.
Flow cytometry
Following transfection cells were stained for apoptosis as
well as apoptosis/necrosis using the annexin V test kit
from Becton Dickinson (San José, USA). Flow cytometric
cell analysis and quantification of cell death took place
on a flow cytometer (CyFlow Space, Partec, Germany) as
described previously [46,47].
Consent
Written informed consent was obtained from the pa-
tients for the publication of this report and any accom-
panying images.Additional file
Additional file 1: Table S1. Sequences of qPCR primers used in this
study.
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